SLNO insider trading

NasdaqCM Healthcare

SOLENO THERAPEUTICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
600
Last 90 days
8
Buys / sells
17% / 51%
Market cap
$2.13B

About SOLENO THERAPEUTICS INC

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Company website: soleno.life

SLNO insider activity at a glance

FilingIQ has scored 600 insider transactions for SLNO since Jul 6, 2017. The most recent filing in our index is dated Mar 27, 2026.

Across the full history, 101 open-market purchases and 303 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SLNO insider trades is 54.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SLNO trades on FilingIQ Raw filings on SEC EDGAR

Latest SLNO Form 4 filings

Mackaness James H
S Mar 27, 2025
Anish Bhatnagar
S Mar 27, 2025
Mackaness James H
S Jul 1, 2024
Mackaness James H
S Dec 11, 2023
Anish Bhatnagar
S Dec 11, 2023
Mackaness James H
S Nov 30, 2023
Mackaness James H
S Nov 28, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098
UNITED THERAPEUTICS Corp
APLS 279
Apellis Pharmaceuticals, Inc.
KMDA 218
KAMADA LTD
BMY 185
BRISTOL MYERS SQUIBB CO
ADPT 184
Adaptive Biotechnologies Corp
GH 169
Guardant Health, Inc.
ISRG 166
INTUITIVE SURGICAL INC
VTRS 165
Viatris Inc

13F funds holding SLNO

Avoro Capital Advisors LLC
$134.27M · 1.3% of AUM
Nantahala Capital Management, LLC
$125.75M · 7.3% of AUM
PERCEPTIVE ADVISORS LLC
$107.65M · 3.8% of AUM
Siren, L.L.C.
$51.97M · 2.9% of AUM
Ikarian Capital, LLC
$24.20M · 2.7% of AUM

Frequently asked

How many insider trades does FilingIQ track for SLNO?
FilingIQ tracks 600 Form 4 insider transactions for SLNO (SOLENO THERAPEUTICS INC), covering filings from Jul 6, 2017 onwards. 8 of those were filed in the last 90 days.
Are SLNO insiders net buyers or net sellers?
Across the full Form 4 history for SLNO, 101 transactions (17%) were open-market purchases and 303 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SLNO insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SLNO in?
SOLENO THERAPEUTICS INC (SLNO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.13B.

Methodology & sources

Every SLNO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.